Clinical Trial Reports Improved Survival Among Advanced Lung Cancer Patients Using “Combination Approach”

A new clinical trial recently reported in the Journal of Clinical Oncology found that combining stereotactic body radiation therapy (SBRT) with chemotherapy improved survival rates among 24 stage IV lung cancer patients.

“SBRT is a type of radiation therapy in which a few very high doses of radiation are delivered from multiple angles to small, well-defined tumors,” said the study’s author, Dr. Robert Timmerman. “The goal is to deliver a radiation dose high enough to kill the cancer, while minimizing exposure to surrounding healthy tissue and organs.”

The combination of chemotherapy with SBRT resulted in a median overall survival of 20.4 months compared to the usual 6- to 9-month overall survival among patients who only received chemotherapy. The combination treatment approach also resulted in improved progression-free survival.

To read more results from this clinical trial, click here.

Columbus CyberKnife treats early and advanced stage lung cancer with SBRT using CyberKnife® technology, an advanced radiosurgery system that delivers targeted doses of radiation to tumors in five or fewer treatments. To learn more about this advanced, cancer-fighting technology contact our center.

This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.